LMLN

Summary

LMLN (leishmanolysin like peptidase, HGNC:15991) is a protein-coding gene on chromosome 3q29, encoding Leishmanolysin-like peptidase (Q96KR4). Metalloprotease.

This gene encodes a zinc-metallopeptidase. The encoded protein may play a role in cell migration and invasion. Studies of a similar protein in Drosophila indicate a potential role in mitotic progression. Alternatively spliced transcript variants have been described.

Source: NCBI Gene 89782 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 87 total
• MANE Select transcript: NM_001136049

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:15991
Approved symbol	LMLN
Name	leishmanolysin like peptidase
Location	3q29
Locus type	gene with protein product
Status	Approved
Aliases	Gp63, Msp, LMNL1
Ensembl gene	ENSG00000185621
Ensembl biotype	protein_coding
OMIM	609380
Entrez	89782

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 10 protein_coding, 6 retained_intron

ENST00000330198, ENST00000332636, ENST00000419117, ENST00000420910, ENST00000451139, ENST00000472063, ENST00000473676, ENST00000476356, ENST00000480813, ENST00000482695, ENST00000482837, ENST00000909098, ENST00000909099, ENST00000909100, ENST00000954517, ENST00000954518

RefSeq mRNA: 2 — MANE Select: NM_001136049 NM_001136049, NM_033029

CCDS: CCDS3332, CCDS46988

Canonical transcript exons

ENST00000420910 — 17 exons

Exon	Start	End
ENSE00001621230	198038567	198043720
ENSE00001910733	197960217	197960440
ENSE00003463523	197996175	197996282
ENSE00003464143	198035833	198036043
ENSE00003478306	198003015	198003125
ENSE00003514432	198021446	198021605
ENSE00003565972	197990559	197990676
ENSE00003585310	197999266	197999342
ENSE00003628922	198019253	198019385
ENSE00003637139	197983943	197984048
ENSE00003644948	197985796	197985890
ENSE00003689636	198024658	198024788
ENSE00003964383	197976598	197976715
ENSE00003964384	197976029	197976111
ENSE00003964385	197975042	197975072
ENSE00003964386	197980326	197980504
ENSE00003964387	197974377	197974474

Expression profiles

Bgee: expression breadth ubiquitous, 235 present calls, max score 95.25.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 9.1208 / max 162.1670, expressed in 1762 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
40788	9.1208	1762

Top tissues by expression

252 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
bronchial epithelial cell	CL:0002328	95.25	gold quality
oviduct epithelium	UBERON:0004804	94.97	gold quality
corpus epididymis	UBERON:0004359	94.33	gold quality
bronchus	UBERON:0002185	93.99	gold quality
secondary oocyte	CL:0000655	93.85	gold quality
caput epididymis	UBERON:0004358	92.76	gold quality
mucosa of paranasal sinus	UBERON:0005030	92.64	gold quality
Brodmann (1909) area 23	UBERON:0013554	90.68	gold quality
cauda epididymis	UBERON:0004360	90.11	gold quality
pancreatic ductal cell	CL:0002079	89.15	gold quality
sperm	CL:0000019	88.27	gold quality
oocyte	CL:0000023	87.34	gold quality
middle temporal gyrus	UBERON:0002771	85.82	gold quality
right uterine tube	UBERON:0001302	85.81	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.81	gold quality
tibia	UBERON:0000979	84.79	gold quality
kidney epithelium	UBERON:0004819	84.54	silver quality
visceral pleura	UBERON:0002401	84.28	gold quality
primary visual cortex	UBERON:0002436	83.49	gold quality
lateral nuclear group of thalamus	UBERON:0002736	82.70	gold quality
epithelial cell of pancreas	CL:0000083	82.02	silver quality
fallopian tube	UBERON:0003889	81.60	gold quality
occipital lobe	UBERON:0002021	81.36	gold quality
skin of hip	UBERON:0001554	81.13	gold quality
testis	UBERON:0000473	80.54	gold quality
right testis	UBERON:0004534	80.12	gold quality
left testis	UBERON:0004533	80.09	gold quality
buccal mucosa cell	CL:0002336	79.54	gold quality
entorhinal cortex	UBERON:0002728	79.39	gold quality
lateral globus pallidus	UBERON:0002476	78.82	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.89
E-ENAD-17	no	460.18

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

205 targeting LMLN, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-4775	99.98	75.00	6394
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790
HSA-LET-7F-5P	99.98	72.56	1784
HSA-LET-7G-5P	99.98	72.37	1784
HSA-LET-7I-5P	99.98	72.37	1788

Literature-anchored findings (GeneRIF, showing 3)

• Functional characterization of a similar protein in Drosophila and comparative studies with the human protein. (PMID:15557119)
• Immunofluorescent detection of human invadolysin in cultured cells reveals the protein to be associated with the surface of lipid droplets. (PMID:19706689)
• miR-17-3p promotes the proliferation of multiple myeloma cells by downregulating P21 expression through LMLN inhibition. (PMID:33609405)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	lmln	ENSDARG00000061265
mus_musculus	Lmln	ENSMUSG00000022802
rattus_norvegicus	Lmln	ENSRNOG00000001781
drosophila_melanogaster	Invadolysin	FBGN0086359
caenorhabditis_elegans		WBGENE00012796

Protein

Protein identifiers

Leishmanolysin-like peptidase — Q96KR4 (reviewed: Q96KR4)

Alternative names: Invadolysin

All UniProt accessions (5): A0AAA9XCN5, B4DR62, C9JF40, F8WCE5, Q96KR4

UniProt curated annotations — full annotation on UniProt →

Function. Metalloprotease.

Subcellular location. Cytoplasm. Lipid droplet.

Tissue specificity. Expressed in all cell lines analyzed.

Cofactor. Binds 1 zinc ion per subunit.

Similarity. Belongs to the peptidase M8 family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q96KR4-1	1	yes
Q96KR4-2	2
Q96KR4-3	3

RefSeq proteins (2): NP_001129521, NP_149018 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001577	Peptidase_M8	Family

Pfam: PF01457

UniProt features (9 total): binding site 3, splice variant 2, chain 1, active site 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96KR4-F1	81.59	0.41

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 265

Ligand- & substrate-binding residues (3): 264; 268; 370

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 130 (showing top): GOMF_METALLOPEPTIDASE_ACTIVITY, FONTAINE_PAPILLARY_THYROID_CARCINOMA_DN, TGGNNNNNNKCCAR_UNKNOWN, CERVERA_SDHB_TARGETS_1_UP, GOBP_CELL_DIVISION, GOBP_PROTEOLYSIS, GEORGES_TARGETS_OF_MIR192_AND_MIR215, GOMF_PEPTIDASE_ACTIVITY, THUM_SYSTOLIC_HEART_FAILURE_DN, KARLSSON_TGFB1_TARGETS_UP, WAKABAYASHI_ADIPOGENESIS_PPARG_BOUND_8D, REICHERT_MITOSIS_LIN9_TARGETS, VANOEVELEN_MYOGENESIS_SIN3A_TARGETS, GOCC_LIPID_DROPLET, ELF2_TARGET_GENES

GO Biological Process (3): proteolysis (GO:0006508), cell adhesion (GO:0007155), cell division (GO:0051301)

GO Molecular Function (5): metalloendopeptidase activity (GO:0004222), peptidase activity (GO:0008233), metal ion binding (GO:0046872), metallopeptidase activity (GO:0008237), hydrolase activity (GO:0016787)

GO Cellular Component (5): cytoplasm (GO:0005737), lipid droplet (GO:0005811), cytosol (GO:0005829), focal adhesion (GO:0005925), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
cellular process	2
protein metabolic process	1
endopeptidase activity	1
metallopeptidase activity	1
hydrolase activity	1
catalytic activity, acting on a protein	1
cation binding	1
peptidase activity	1
catalytic activity	1
intracellular anatomical structure	1
intracellular membraneless organelle	1
cytoplasm	1
cell-substrate junction	1

Protein interactions and networks

STRING

524 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LMLN	C3	P01024	881
LMLN	FN1	P02751	796
LMLN	HSPA4	P34932	662
LMLN	ERV3-1	Q14264	598
LMLN	ERVFRD-1	P60508	597
LMLN	PTS	Q03393	593
LMLN	ARG1	P05089	585
LMLN	ERVW-1	Q9UQF0	583
LMLN	ARG2	P78540	576
LMLN	SERPINH1	P29043	542
LMLN	DICER1	Q9UPY3	532
LMLN	F8W876	F8W876	512
LMLN	VWA7	Q9Y334	473
LMLN	IFNG	P01579	472
LMLN	CPB1	P15086	450

IntAct

25 interactions, top by confidence:

A	B	Type	Score
ISLR	BCKDK	psi-mi:“MI:0914”(association)	0.530
CLGN	NPC1	psi-mi:“MI:0914”(association)	0.530
P		psi-mi:“MI:0914”(association)	0.350
SHANK3	IGKV3D-15	psi-mi:“MI:0914”(association)	0.350
PIP	RBM47	psi-mi:“MI:0914”(association)	0.350
CLEC12B	GXYLT2	psi-mi:“MI:0914”(association)	0.350
LLCFC1	POTEF	psi-mi:“MI:0914”(association)	0.350
BRICD5	POTEF	psi-mi:“MI:0914”(association)	0.350
RLN1	RTL8C	psi-mi:“MI:0914”(association)	0.350
F9	APBB1	psi-mi:“MI:0914”(association)	0.350
IGFL3	CBX4	psi-mi:“MI:0914”(association)	0.350
LYPD4	PIK3C2A	psi-mi:“MI:0914”(association)	0.350
TAFAZZIN	MANBA	psi-mi:“MI:0914”(association)	0.350
SLURP1	MANBA	psi-mi:“MI:0914”(association)	0.350
TMEM25	NME4	psi-mi:“MI:0914”(association)	0.350
TRAV20	MAP2K7	psi-mi:“MI:0914”(association)	0.350
DEFB125	ZZEF1	psi-mi:“MI:0914”(association)	0.350
LCN6	COCH	psi-mi:“MI:0914”(association)	0.350
WFDC11	PLXNA2	psi-mi:“MI:0914”(association)	0.350
PON2	ENTPD6	psi-mi:“MI:0914”(association)	0.350
IL17RB	ATP1A3	psi-mi:“MI:0914”(association)	0.350
LMLN	PRSS53	psi-mi:“MI:0914”(association)	0.350
SLC44A1	UPK3BL1	psi-mi:“MI:0914”(association)	0.350
INSR	BLTP3B	psi-mi:“MI:0914”(association)	0.350

BioGRID (43): LMLN (Affinity Capture-MS), LMLN (Affinity Capture-MS), LMLN (Synthetic Growth Defect), LMLN (Affinity Capture-MS), LMLN (Affinity Capture-MS), LMLN (Affinity Capture-MS), LMLN (Affinity Capture-MS), LMLN (Affinity Capture-MS), LMLN (Affinity Capture-MS), LMLN (Affinity Capture-RNA), LMLN (Affinity Capture-RNA), LMLN (Synthetic Lethality), LMLN (Affinity Capture-MS), LMLN (Affinity Capture-MS), NLN (Affinity Capture-MS)

ESM2 similar proteins: A0A1B0GTW7, A0A1D5NSK0, A0A1L8HYT7, A0A286YEC0, D3ZT86, D3ZWJ9, D4A929, F8W3R9, G7PWZ3, I6M4H4, O08852, O43157, O43278, O75074, O88204, P17813, P49000, P59383, Q04912, Q17R55, Q499Z3, Q4R3B7, Q4TUC0, Q5ND34, Q62190, Q63961, Q6AXX1, Q76MJ5, Q7TN88, Q7TQH7, Q7Z442, Q7Z4F1, Q80W87, Q80YN4, Q866Y3, Q86VZ4, Q8BHW9, Q8BMN4, Q8BYI8, Q8BZT7

Diamond homologs: A0A1B0GTW7, A0A1L8HYT7, A0A286YEC0, O62446, Q29AK2, Q61YG1, Q8BMN4, Q96KR4, Q9VH19, A0A1D5NSK0

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

87 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	63
Likely benign	4
Benign	6

Top pathogenic / likely-pathogenic (0)

SpliceAI

3136 predictions. Top by Δscore:

Variant	Effect	Δscore
3:197974372:TTCA:T	acceptor_loss	1.0000
3:197974373:TCAG:T	acceptor_loss	1.0000
3:197974374:CAG:C	acceptor_loss	1.0000
3:197974375:A:AG	acceptor_gain	1.0000
3:197974375:AG:A	acceptor_gain	1.0000
3:197974376:G:GA	acceptor_gain	1.0000
3:197974376:GG:G	acceptor_gain	1.0000
3:197974376:GGT:G	acceptor_gain	1.0000
3:197974376:GGTC:G	acceptor_gain	1.0000
3:197974376:GGTCA:G	acceptor_gain	1.0000
3:197974470:GAAGA:G	donor_gain	1.0000
3:197974471:AAGA:A	donor_gain	1.0000
3:197974472:AGA:A	donor_gain	1.0000
3:197974472:AGAGT:A	donor_loss	1.0000
3:197974473:GA:G	donor_gain	1.0000
3:197974473:GAG:G	donor_gain	1.0000
3:197974473:GAGTA:G	donor_loss	1.0000
3:197974474:AG:A	donor_loss	1.0000
3:197974475:G:GG	donor_gain	1.0000
3:197974475:GTAA:G	donor_loss	1.0000
3:197974476:TAA:T	donor_loss	1.0000
3:197976016:A:AG	acceptor_gain	1.0000
3:197976017:A:G	acceptor_gain	1.0000
3:197976564:T:A	acceptor_gain	1.0000
3:197976567:A:AG	acceptor_gain	1.0000
3:197976568:T:G	acceptor_gain	1.0000
3:197976571:A:AG	acceptor_gain	1.0000
3:197976573:A:AG	acceptor_gain	1.0000
3:197976573:ACTTT:A	acceptor_gain	1.0000
3:197976577:T:A	acceptor_gain	1.0000

AlphaMissense

4520 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:198019341:T:A	C441S	1.000
3:198019341:T:C	C441R	1.000
3:198019342:G:A	C441Y	1.000
3:198019342:G:C	C441S	1.000
3:198021539:T:C	F487L	1.000
3:198021540:T:G	F487C	1.000
3:198021541:C:A	F487L	1.000
3:198021541:C:G	F487L	1.000
3:198021547:G:C	W489C	1.000
3:198021547:G:T	W489C	1.000
3:198021581:T:A	C501S	1.000
3:198021581:T:C	C501R	1.000
3:198021582:G:A	C501Y	1.000
3:198021582:G:C	C501S	1.000
3:198021583:T:G	C501W	1.000
3:198024705:T:A	C525S	1.000
3:198024705:T:C	C525R	1.000
3:198024706:G:A	C525Y	1.000
3:198024706:G:C	C525S	1.000
3:198024707:T:G	C525W	1.000
3:198024780:T:A	C550S	1.000
3:198024780:T:C	C550R	1.000
3:198024781:G:C	C550S	1.000
3:197984028:C:G	H272D	0.999
3:197984029:A:C	H272P	0.999
3:197984030:T:A	H272Q	0.999
3:197984030:T:G	H272Q	0.999
3:197984032:A:T	E273V	0.999
3:197985799:T:C	F280L	0.999
3:197985801:C:A	F280L	0.999

dbSNP variants (sampled 300 via entrez): RS1000022773 (3:198031563 T>C), RS1000052302 (3:197979918 G>A), RS1000141323 (3:198022640 G>T), RS1000172906 (3:197972652 C>A,T), RS1000186094 (3:197965481 T>C), RS1000189544 (3:197989270 C>T), RS1000224685 (3:197973984 C>A,T), RS1000269576 (3:197960929 A>G), RS1000275653 (3:198043659 A>G,T), RS1000322224 (3:198019858 T>C), RS1000397904 (3:198037189 A>C,G), RS1000404148 (3:198035365 T>TTTC,TTTG), RS1000415520 (3:198035640 G>A), RS1000448842 (3:198036863 T>A,C), RS1000449224 (3:197985648 G>A)

Disease associations

OMIM: gene MIM:609380 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST004571_17	Iron status biomarkers (total iron binding capacity)	3.000000e-07
GCST004572_30	Iron status biomarkers (transferrin saturation)	3.000000e-07

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0006334	total iron binding capacity

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

32 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases expression	3
p-Chloromercuribenzoic Acid	affects cotreatment, decreases expression	2
GSK-J4	decreases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	increases expression	1
sodium arsenite	decreases expression	1
tobacco tar	increases expression	1
benzo(e)pyrene	increases methylation	1
avobenzone	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
(+)-JQ1 compound	increases expression	1
Sunitinib	decreases expression	1
Vehicle Emissions	decreases expression, increases abundance	1
Benzo(a)pyrene	decreases methylation	1
Cadmium	decreases expression, increases abundance	1
Succimer	affects cotreatment, increases expression	1
Doxorubicin	decreases expression	1
Methapyrilene	increases methylation	1
Methyl Methanesulfonate	increases expression	1
Oxygen	increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Urethane	decreases expression	1
Cyclosporine	increases expression	1
Aflatoxin B1	increases methylation	1
Cadmium Chloride	decreases expression, increases abundance	1
Okadaic Acid	decreases expression	1
Acrylamide	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer